New Hypertension in a Competitive Shooter: Why the Obvious First Drug Isn't the Right One
Confirmed sustained hypertension in a nationally-ranked competitive pistol shooter, whose sport bans beta-blockers at all times, in and out of competition. The real reason to avoid one turns out to have little to do with the ban itself.
A.V., a 38-year-old woman, has competed nationally in precision pistol shooting for over a decade, training most mornings before work and traveling to sanctioned matches several weekends a year — her sport has adopted the World Anti-Doping Code, and she has been drug-tested at competitions before. Her mother was diagnosed with hypertension at 45, and at a routine physical, her blood pressure read 152/94. Two weeks of home monitoring, taken well away from any competition or training stress, averaged 148/92 — genuinely sustained elevation, not a one-off reading or a competition-day adrenaline spike. She has no other medical history, doesn't smoke, and is otherwise fit; a baseline echocardiogram today shows no LVH yet, though her family history puts her at real risk of developing it if her blood pressure goes untreated. Her physician's first instinct was a beta-blocker — a familiar, well-established antihypertensive — before remembering that beta-blockers sit on WADA's Prohibited List specifically for shooting, archery, and underwater sports, and unlike most other sports where the ban applies only during competition, hers bans the drug class at all times, in and out of competition, precisely because of its tremor-steadying effect.
A therapeutic use exemption exists for athletes who have a genuine, well-documented medical need for a prohibited substance, and hypertension is a recognized qualifying condition in principle — but a TUE has to be applied for and approved, carries real administrative uncertainty, and would need renewal on an ongoing basis for a chronic condition. The more direct question, though, is whether a beta-blocker was ever the right first choice for her independent of the doping issue. Current hypertension guidelines do not rank beta-blockers as first-line therapy for uncomplicated primary hypertension without a compelling comorbid indication — coronary disease, heart failure, certain arrhythmias — none of which A.V. has. A thiazide, ACE inhibitor, ARB, or calcium channel blocker is already the guideline-preferred starting point regardless of her sport. Among those options, the LIFE trial found losartan produced significantly greater regression of LVH than atenolol at similar blood-pressure control — a specific, positive reason to reach for an ARB rather than simply the absence of a beta-blocker's downside.
Cardiology consult, new hypertension diagnosis
I don't think we should rule out a beta-blocker just because of the sport. A TUE process exists exactly for cases like this — a real medical need for a substance that happens to be restricted. Discarding an otherwise reasonable option over an administrative hurdle undersells a real treatment path.
I'd still want to hear whether there's a cleaner option before pursuing that path — I'm not committed to a beta-blocker specifically, just resisting ruling it out reflexively.
There's a cleaner option, and it doesn't require the doping question at all. Beta-blockers were never guideline first-line for uncomplicated hypertension without a compelling comorbid indication — she has no coronary disease, no heart failure, no arrhythmia. A thiazide, ACE inhibitor, ARB, or calcium channel blocker is already the correct starting point for her, sport aside. The TUE conversation is solving a problem that doesn't need to exist here.
I don't think the TUE pathway is illegitimate in general — I think reaching for it here would be treating a non-issue as a real obstacle.
If we're choosing among the non-beta-blocker options, that choice has real comparative data behind it too, not just default equivalence. The LIFE trial found losartan produced significantly greater LVH regression than atenolol at matched blood-pressure control. Her echo is clean today, but her family history puts her at real risk if this goes untreated — an ARB gives her a positive reason to prefer it, not just the absence of a downside.
Agreed: start losartan 50mg daily, recheck home blood pressure readings and basic metabolic panel in four weeks, and repeat echocardiogram in a year to confirm LVH prevention rather than just symptom control.
Not agreed, and carried forward explicitly rather than smoothed over:
A calcium channel blocker or thiazide add-on is the agreed next step — the Cardiologist's TUE pathway remains available in principle but was not the group's preferred fallback.
Maintains that ruling out a beta-blocker over sport eligibility alone, without a clinical reason, would have been the wrong instinct — accepted today's outcome because a better clinical reason existed, not because the doping question settled it.
The Sports Medicine Physician's core point — that this case looked harder than it actually was once the real guideline recommendation was applied — was accepted by both other voices as the actual basis for today's plan.